Favorable remission control by allogeneic stem cell transplantation in NPM1 positive intermediate-risk AML: Donor versus no-donor analysis of 302 patients from the SAL AML-2003 trial

被引：0
|
作者：
Roellig, C. [1 ]
Bornhaeuser, M. [1 ]
Thiede, C. [1 ]
Kramer, M. [1 ]
Ho, A. [2 ]
Schaefer-Eckart, K. [3 ]
Haenel, M. [4 ]
Einsele, H. [5 ]
Aulitzy, W. [6 ]
Berdel, W. E. [7 ]
Stelies, M. [7 ]
Baldus, C. [8 ]
Krause, S. W. [9 ]
Platzbecker, U. [1 ]
Schaich, M. [1 ]
Schetelig, J. [1 ]
Ehninger, G. [1 ]
机构：
[1] Univ Klinikum Dresden, Med Klin & Poliklin 1, Dresden, Germany
[2] Univ Klinikum Heidelberg, Med Klin 5, Heidelberg, Germany
[3] Klinikum Nurnberg, Med Klin 5, Nurnberg, Germany
[4] Klinikum Chemnitz, Innere Med Klin 3, Chemnitz, Germany
[5] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[6] Robert Bosch Krankenhaus, Abt Hamatol Onkol & Palliat Med, Stuttgart, Germany
[7] Univ Klinikum Munster, Med Klin & Poliklin A, Munster, Germany
[8] Charite Campus Benjamin Franklin, Med Klin Schwerpunkt Hamatol Onkol, Berlin, Germany
[9] Univ Klinikum Erlangen, Med Klin 5, Erlangen, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：168 / 169
页数：2
相关论文
共 35 条
  • [31] Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT
    Schmid, Christoph
    Labopin, Myriam
    Deconinck, Eric
    Attal, Michel
    Socie, Gerard
    Vigouroux, Stephane
    Volin, Liisa
    Ifrah, Norbert
    Rambaldi, Alessandro
    Rossi, Jean-Francois
    Blaise, Didier
    Cornelissen, Jan
    Ljungman, Per T.
    Brune, Mats L.
    Bordigoni, Pierre
    Vernant, Jean-Paul
    Yakoub-Agha, Ibrahim
    Pogliani, Enrico Maria
    Michallet, Mauricette
    Arcese, William
    Polge, Emmanuelle
    Esteve, Jordi
    Mohty, Mohamad
    BLOOD, 2012, 120 (21)
  • [32] COMBINING AZACITIDINE (VIDAZA®, AzA) AND DONOR LYMPHOCYTE INFUSIONS (DLI) AS FIRST SALVAGE TREATMENT IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROMES (MDS) RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (Allo-SCT): INTERIM-ANALYSIS FROM THE AZARELA-TRIAL (NCT-00795548)
    Schroeder, T.
    Czibere, A. G.
    Kroeger, N.
    Platzbecker, U.
    Bug, G.
    Uharek, L.
    Luft, T.
    Bruns, I
    Zohren, F.
    Wolschke, C.
    Fenk, R.
    Haas, R.
    Kobbe, G.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S159 - S159
  • [33] Phase II Study of Azacitidine (Vidaza®, Aza) and Donor Lymphocyte Infusions (DLI) As First Salvage Therapy in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (allo-SCT): Final Results From the AZARELA-Trial (NCT-00795548)
    Schroeder, Thomas
    Czibere, Akos
    Kroeger, Nicolaus
    Platzbecker, Uwe
    Bug, Gesine
    Uharek, Lutz
    Luft, Thomas
    Wolschke, Christine
    Bruns, Ingmar
    Zohren, Fabian
    Fenk, Roland
    Haas, Rainer
    Kobbe, Guido
    BLOOD, 2011, 118 (21) : 300 - 300
  • [34] Comparison of Low Dose Total Body Irradiation (TBI)-Based Reduced Intensity Conditioning (RIC) Vs. Chemotherapy-Based RIC Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1): a Retrospective Analysis of 1200 Patients From the Acute Leukemia Working Party of EBMT.
    Mohty, Mohamad
    Labopin, Myriam
    Janssen, Jeroen J. W. M.
    Mufti, Ghulam J.
    Cornelissen, J. J.
    Milpied, Noel-Jean
    Sengeloev, Henrik
    Blaise, Didier
    Petersen, Eefke
    Goker, Hakan
    Gribben, John G.
    Nagler, Arnon
    Rocha, Vanderson
    BLOOD, 2009, 114 (22) : 489 - 489
  • [35] Comparison of Busulfan and Cyclophosphamide (Bu-Cy)-Based Standard Myeloablative Conditioning (MAC) Vs. Fludarabine and Busulfan (Flu-Bu)-Based Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR1) Aged >40 Years: a Retrospective Analysis From the Acute Leukemia Working Party of EBMT
    Mohty, Mohamad
    Labopin, Myriam
    Socie, Gerard
    Milpied, Noel-Jean
    Attal, Michel
    Blaise, Didier
    Ringden, Olle
    Brown, Paul
    Lorentz, Brinch
    Brune, Mats L.
    Hamladji, Rose-Marie
    Duarte, Rafael F.
    Nagler, Arnon
    Rocha, Vanderson
    BLOOD, 2009, 114 (22) : 1306 - 1306
1234